The long, tormented regulatory journey Heron Therapeutics Inc. has been on over the past nearly seven years with its chemotherapy-induced nausea and vomiting (CINV) drug Sustol (granisetron) has finally come to a somewhat successful end, with the FDA granting its go-ahead for the product to be marketed in the US, although not for the broad use the company had sought.
The product moves Heron from a research and development company to a commercial enterprise. The question now is whether Heron...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
